



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

28 Feb. 2008

TOWNSEND and TOWNSEND and CREW LLP

By:

Malvinda C. Ogil

PATENT

Attorney Docket No.: 015280-462100US

Client Ref. No.: E-121-2002/0-US-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SHOEMAKER et al.

Application No.: 10/528,747

Filed: March 22, 2005

For: IDENTIFICATION OF ANTI-HIV
COMPOUNDS INHIBITING VIRUS
ASSEMBLY AND BINDING OF
NUCLEOCAPSID PROTEIN TO
NUCLEIC ACID

Customer No.: 45115

Confirmation No. 1785

Examiner: Stuart Snyder

Technology Center/Art Unit: 1648

DECLARATION UNDER 37 C.F.R. §
1.132 BY DR. ROBERT SHOEMAKER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. I, Robert H. Shoemaker, currently hold the position of Chief, Screening Technologies Branch, Developmental Therapeutic Program at the National Cancer Institute at Frederick, Maryland. I am a co-inventor of the subject matter disclosed and claimed in the above-referenced patent application.

2. I received a Ph.D. in human genetics from the Graduate School of Public Health of the University of Pittsburgh in 1975. I joined the National Cancer Institute in 1981 and have held a variety of positions in the extramural Developmental Therapeutics Program relating

to the development and implementation of novel drug screening projects for the treatment of cancer and AIDS. In 1999, I was appointed Chief of the Antiviral Evaluations Branch, a position that has evolved into my present position as Chief of the Screening Technologies Branch. My field of research is the identification and exploitation of molecular targets for drug discovery, development of clinically relevant methods for target monitoring, and natural products-based drug discovery. A copy of my CV is provided as Exhibit A.

3. It is my understanding that the Examiner has rejected claims 1, 2, 7, and 9-17 as allegedly not enabled by the specification because although the specification provides exemplary data showing *in vitro* activity of the claimed compounds, no data are presented in the examples to illustrate the activity of the compound *in vivo*. This Declaration provides additional data as further evidence that the specification enables one of ordinary skill in the art to use the compounds *in vivo* to inhibit proliferation of a human immunodeficiency virus.

4. An exemplary compound having a structure as claimed was evaluated *in vivo* using the SCID-hu mouse model (McCune et al., *Science* 241:1632-1639 (1988)) that was developed for the study of HIV-1 pathogenesis *in vivo*. This model is constructed by transplantation of interactive human lymphoid organs into immunodeficient CB-17-scid mice. The SCID-hu model has been optimized by use of conjoint implants of human fetal thymus and liver to create the SCID-hu Thy/Liv mouse. These organs fuse, become vascularized, and grow when implanted beneath the kidney capsule, eventually reaching a total mass of 10^7 - 10^8 human cells in 80—90% of recipient mice (Namikawa et al., *J. Exp. Med.* 172:1055-1063 (1990)). A stable organ termed "Thy/Liv" is thus established with histologically normal cortical and medullary compartments that are capable of multilineage human hematopoiesis and generating a continuous source of human CD4⁺ T cells for 6—12 months (Krowka et al., *J. Immunol.* 145:3751-3756 (1991); Namikawa et al., *J. Exp. Med.* 172:1055-1063 (1990); Vandekerckhove et al., *J. Exp. Med.* 176:1619-1624 (1992); Vandekerckhove et al., *J. Immunol.* 146:4173-4179 (1991)). The implants support viral replication after inoculation of HIV-1 by direct injection (Namikawa et al., *Science* 242:1684-1686 (1988)), and thymocyte depletion occurs with some

viral isolates within 3—5 weeks (Aldrovandi et al., *Nature* 363:732-736 (1993); Berkowitz et al., *J. Virol.* 72:10108-10117 (1998); Bonyhadi et al., *Nature* 363:728-732 (1993); Kaneshima et al., *J. Virol.* 68:8188-8192 (1994); Stanley et al., *J. Exp. Med.* 178:1151-1163 (1993)). This depletion includes loss of CD4⁺CD8⁺ immature cortical thymocytes and a decrease in the CD4/CD8 ratio in the thymic medulla. Administration of nucleoside (AZT, ddl, 3TC) and nonnucleoside (nevirapine) reverse transcriptase inhibitors to these mice results in dose-dependent inhibition of HIV-1 replication (and protection of CD4⁺ cells) within the implanted human tissue (Namikawa et al., *Science* 242:1684-1686 (1988); Stanley et al., *J. Exp. Med.* 178:1151-1163 (1993); Stoddart et al., *Antimicrob. Agents Chemother.* 42:2113-2115 (1998)). The model has been also used to evaluate new classes of HIV-1 inhibitors, such as bicyclam (Datema et al., *Antimicrob. Agents Chemother.* 40:750-754 (1996)) and oligonucleotide (Stoddart et al., *Antimicrob. Agents Chemother.* 42:2113-2115 (1998)) inhibitors of HIV-1 entry, the nucleoside analog dOTC (Stoddart et al., *Antimicrob. Agents Chemother.* 44:783-786 (2000)), and an oxime-piperidine CCR5 antagonist (Strizki et al., *Proc. Natl. Acad. Sci. USA* 98:12718-12723 (2001)).

5. The data presented in this Declaration were obtained using a representative pentavalent antimony-containing small molecule of the invention (designated NSC 13778). The compound has an EC₅₀ of 1 μM and selectivity index of greater than 426 in CEM-SS cells infected with the HIV-1 isolated RF. A toxicity study of NSC-13778 in the mouse model demonstrated that twice-daily subcutaneous injections of NSC 13778 at 2-60 mg/kg/day for 21 days caused no apparent toxicity or body weight loss (Figure 1, provided in Exhibit B). Treatment also did not cause thymocyte depletion or perturbations in thymocyte subpopulations except for a minor decrease in CD4/CD8 ratio (from 2.9 to 2.0) at 60 mg/kg/day.

6. A total of 45 mice were evaluated in the antiviral efficacy experiments described here. Thy/Liv mice were inoculated with HIV-1 by direct injection of 1,250 TCID₅₀ into each Thy Liv/implant. Mice were divided into seven groups (A-G) of seven animals each. Group A through F mice were inoculated with virus and group G mice were mock-inoculated. Groups A, B, and C were treated with NSC 13778. The drug 3TC was administered to animals

in group D as a positive control (it is known to inhibit HIV-1 viral infection); vehicle alone (group E) was used as a negative control. Mice in groups F and G were not treated with either drug or vehicle. All mice were dosed by subcutaneous injection (150 μ L per dose) twice-daily throughout the treatment course. The amounts administered were: 60 mg/kg/day NSC13778 (group A), 20 mg/kg/day NSC13778 (group B), 6 mg/kg/day NSC13778 (group C), 30 mg/kg/day 3TC (group D), and vehicle only, 0.05 M NaOH, (group E). Groups A-G were treated for 1 day, inoculated with virus or mock-inoculated and subsequently treated for 21 days, all as described above. At the end of the 21 days of treatment, Thy/Liv implants were surgically excised from mice in groups A through G in order to examine the effect of NSC 13778 on HIV-1 replication by measuring levels of p24-Gag and HIV-1 RNA. Three mice (one in group B, one in group C, and one in group F) were not used because of poor implant quality or lack of implant. One of the mice in group G was excluded from all implant analyses because of an abnormal cell profile.


7. Post-excising, implant thymocyte samples containing 10^6 cells were pelleted and either lysed for Gag-p24 analysis or stored and subsequently processed by standard methods for RNA isolation and analysis. The levels of p24 were measured by standard ELISA protocols and expressed as pg per 10^6 implant thymocytes. The levels of RNA were detected using the VERSANTTM HIV-1 RNA 3.0 Assay (Bayer Diagnostics, Norwood, Massachusetts) and expressed as RNA copies per 10^6 implant thymocytes. MHC class I detection was performed using fluorescently labeled anti-CD4, anti-CD8, anti-CD3 and anti-CD195 antibodies in a standard FACS analysis.

8. Untreated, HIV-1 infected mice (Group E) had means of 590 ± 87 pg p24 and 5.8 ± 0.15 log₁₀ copies HIV-1 RNA per 10^6 implant cells and $8.6 \pm 1.1\%$ Gag-p24⁺ thymocytes at 21 days after inoculation. These untreated mice also exhibited a 3.1-fold increase in MHC class I expression on CD4⁺CD8⁺ immature cortical thymocytes. Substantial reductions in CD4⁺CD8⁺ thymocytes (from 82% to 33%), CD4/CD8 ratio (from 1.7 to 0.67) and thymocyte viability (from 83% to 52%) in infected compared to mock-infected implants also were observed at 21 days after virus inoculation.

9. Thy/Liv mice that were treated with NSC 13778 at 60 mg/kg/day exhibited statistically significant reductions in p24, from 590 to 210 pg p24 per 10^6 cells (Figure 2, provided in Exhibit B). The 60 mg/kg/day treatment also reduced the HIV-1 viral RNA from $5.8 \log_{10}$ to $4.9 \log_{10}$ copies per 10^6 cells and Gag-p24⁺ thymocytes from 8.6% to 4.9% as compared to non-NSC 13778 treated, HIV-1 infected controls (also Figure 2), however, there were no significant reductions in MHC class I expression on CD4⁺CD8⁺ thymocytes from NSC 13778-treated mice compared to implants from untreated, HIV-1 infected control mice. Treatment with NSC 13778 did not protect thymocytes from virus-mediated depletion.

10. These data show dose-related inhibition of viral replication in response to treatment with NSC 13778 as assessed by p24 viral core antigen levels and HIV RNA levels (Figure 2). These experiments therefore provide additional evidence that the specification enables one of ordinary skill in the art to use the compound of the invention *in vivo* to inhibit proliferation of a virus.

11. I further declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both (18 U.S.C. § 1001), and may jeopardize the validity of the patent application or any patent issuing thereon.

Dated: 2/28/08 

Robert H. Shoemaker, Ph.D.

Exhibit A

February 2008

CURRICULUM VITAE

Robert H. Shoemaker, Ph.D.

EMPLOYMENT ADDRESS:

Screening Technologies Branch
Developmental Therapeutics Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Frederick Research and Development Center
Building 440, Room 1
Frederick, Maryland 21702-1201

Office Phone: 301-846-6845

FAX: 301-846-6844

Internet: shoemaker@dpax2.ncifcrf.gov

EDUCATION:

1971 B.S., College of Arts and Sciences, University of Pittsburgh,
Pittsburgh, Pennsylvania

1973 M.S. in Human Genetics, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, Pennsylvania

1975 Ph.D. in Human Genetics, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, Pennsylvania

EMPLOYMENT:

Research Assistant, Cytogenetics Laboratory, Department of Radiation Health, University of Pittsburgh,
Pittsburgh, Pennsylvania, October, 1972-April, 1973.

Research Associate, Shadyside Hospital Institute of Pathology, Pittsburgh, Pennsylvania, May,
1973-September, 1973.

Chief, Experimental Pathology, Shadyside Hospital Institute of Pathology, Pittsburgh, Pennsylvania,
September, 1973-April, 1975.

Captain, Medical Service Corps, U.S. Army, assigned to the Department of Cellular Pathology, Armed
Forces Institute of Pathology, Walter Reed Army Medical Center, Washington, D.C., July, 1975-May,
1977.

EMPLOYMENT:

Senior Research Associate, Department of Pathology, Children's Hospital Medical Center of Akron, Akron, Ohio; Consultant, Genetics Clinic, Children's Hospital Medical Center of Akron, June, 1977-November, 1981.

Acting Head, Cell Culture Section, Drug Evaluation Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, November, 1981-February, 1985.

Head, Cell Culture Section, Drug Evaluation Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, February, 1985-April, 1986.

Special Assistant for Research and Development, Office of the Associate Director, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, MD, April, 1986-February, 1988.

Acting Chief, Information Technology Branch, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, February, 1988-July, 1989.

Special Assistant for Research and Development, Office of the Associate Director Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute National Institutes of Health, Bethesda, MD, July, 1989-February 1990.

Senior Investigator, Cell Biology, Biochemistry, and Experimental Therapeutics Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research and Development Center, February, 1990-February, 1994.

Acting Head, Cell Biology, Biochemistry, and Experimental Therapeutics Section Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program Division of Cancer Treatment, National Cancer Institute Frederick Cancer Research and Development Center, February, 1994-February 1995.

Head, Biology Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, Frederick Cancer Research and Development Center, February, 1995-February, 1996.

Senior Investigator, Discovery Section, Laboratory of Drug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis and Centers, National Cancer Institute, Frederick Cancer Research and Development Center, February, 1996-August, 1999.

EMPLOYMENT:

Acting Chief, Antiviral Evaluations Branch, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, National Cancer Institute, Bethesda, Maryland, February, 1998-August, 1999.

Acting Chief, Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, National Cancer Institute, Bethesda, Maryland, August, 1999-June, 2000.

Chief, Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, National Cancer Institute, Bethesda, Maryland, June, 2000-present.

COMMITTEE APPOINTMENTS (Selected Listing):

Member, Drug Evaluation Committee, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1981-1985.

Member, Biological Evaluation Committee (Cancer), Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1985-1989.

Member, Decision Network Committee, Division of Cancer Treatment, National Cancer Institute, 1987-1989.

Member, Drug Screening Acquisitions and Input Committee, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1988-1989.

Member, Operating Committee, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1988-1989.

Member, Developmental Therapeutics Program Senior Staff Contract Review Committee, National Cancer Institute, 1988-1989.

Member, Biological Evaluation Committee (AIDS), Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 1987-1989.

Member, AIDS In Vivo Models Committee, AIDS Program, National Institute of Allergy and Infectious Diseases, 1988-1989.

Scientific Program Committee, 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1995.

Member, Thesis Examination Committee (doctoral thesis of Miguel A. Izquierdo, M.D.), Free University of Amsterdam, The Netherlands, February, 1996.

COMMITTEE APPOINTMENTS (Selected Listing):

Member, National Institutes of Health Inter-Institute Working Group on Hepatitis C, February 1998-2000.

Scientific Program Committee, 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Frankfurt, Germany, November, 2002.

Member, Radiation Modifier Working Group of the National Cancer Institute, 2002.

Scientific Program Committee, 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland, September, 2004.

LECTURES PRESENTED AT MAJOR SYMPOSIA (Selected Listing)

Speaker, Third Conference on Human Tumor Cell Cloning, Tucson, AZ, January, 1981.

Invited Speaker, 13th International Cancer Congress, Seattle, WA, September 8-15, 1982

Speaker, US-Japan Eighth Annual Treatment Program Area Review Meeting, Bethesda, Maryland, November 22-24, 1982.

Organizer, Chairman, and Speaker, National Cancer Institute Symposium: "Cellular Resistance to Anti-Cancer Drugs", Bethesda, Maryland, February 25, 1983.

Invited Speaker, US-Japan Joint Seminar on Anticancer Drug Resistance, Honolulu, HA, May 30 - June 1, 1983.

Invited Speaker, National Cancer Institute Symposium: "Discovery and Development of Naturally Occurring Antitumor Drugs", Frederick, Maryland, June 27-29, 1983.

Invited Speaker, Fourth Conference on Human Tumor Cloning, Tucson, AZ, January 8-10, 1984.

Invited Lecture, 12th International Chemotherapy Congress, Vienna, Austria, 1984.

Invited Lecture, Symposium on Drug Discovery, Behringwerke, Marburg, West Germany, 1984.

Co-organizer (with Dr. Michael Boyd) and Speaker, NCI Workshop on "Disease-Oriented Antitumor Drug Discovery and Development", Bethesda, Maryland, January 9-10, 1985.

Invited Speaker, Early Clinical Trials - Preclinical Screening and Pharmacokinetic Group Meetings of the European Organization for Research and Treatment of Cancer (EORTC), Lugano, Switzerland, May 31, 1985.

LECTURES PRESENTED AT MAJOR SYMPOSIA (Selected Listing)

Session Co-Chairman (with Dr. Takashi Tsuruo) and Speaker, Symposium on "Resistance to Anticancer Drugs", 14th International Chemotherapy Congress, Kyoto, Japan, June 23-28, 1985.

Invited Lecture, International Union Against Cancer (UICC) - Study Group Meeting, Oslo, Norway, September, 9-11, 1985.

Invited Lecture, Seminar on Human Tumor Xenografts in Anticancer Drug Development, European School of Oncology, Stellite Palace, Milan, Italy, May 26-27, 1986.

Invited Speaker, European Organization for Research and Treatment of Cancer (EORTC) Clonogenic Assay Screening Study Group Meeting, Nijmegen, The Netherlands, June 2-4, 1986.

Invited Lecture, FASEB Summer Conference on "Lung Pharmacology", Saxton's River, Vermont, July 28 - August 1, 1986.

Invited Speaker, First Beijing International Symposium on "Cancer Treatment and New Trends of Cancer Chemotherapy", Beijing, People's Republic of China, September 7-9, 1986.

Invited Speaker, Biochemical Modulators Advisory Group - NCI Phase I Clinical Trials Working Group Meeting, Bethesda, Maryland, November 17, 1986.

Co-organizer (with Dr. Michael Boyd) and Speaker, NCI/NIAID Workshop on "Issues for Implementation of a National Anti-HIV Preclinical Drug Evaluation Program: Critical Parameters for an In Vitro Human Host-Cell Based, Primary Screen", Rockville, Maryland, April 8-9, 1987.

Co-organizer (with Dr. Michael Boyd) and Speaker, NCI Workshop, "Issues Concerning Selection, Characterization and Quality Control of Human Tumor Cell Lines for the National Cancer Institute's New Drug Screening Program", Bethesda, Maryland, May 27-28, 1987.

Invited Lecture, 57th ANZAAS Congress, James Cook University of North Queensland, Townsville, Australia, August 28, 1987.

Invited Speaker, "Horizons on Antibiotic Research", Memorial Symposium Dedicated to Professor Hamao Umezawa, Tokyo, Japan, November 25-26, 1987.

Invited Lecture, Gordon Research Conference, "Mechanisms of Toxicity", Kimball Union Academy, July, 1989.

Co-chairman (with Dr. Emil Frei) and Speaker, Round-table Session: "Discovery, Evaluation, and Development of Anticancer Drugs", International Cancer Congress, Hamburg, Germany, August 22, 1990.

LECTURES PRESENTED AT MAJOR SYMPOSIA (Selected Listing)

Invited Speaker, International Symposium on Cytostatic Drug Resistance, Kiel, Germany, November, 1991.

Co-chairman (with Peter Buhl Jensen, M.D.) and invited speaker, Preclinical Drug Development Session, Second Nordic Symposium on Lung Cancer, Sorrento, Italy, August, 1995.

Co-Chairman (with Alex Matter, M.D.), Session on New Trends in Cell and Animal Screening Models, 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, June, 1998.

Invited Faculty, Graduate Course on "Preclinical and Clinical Pharmacodynamics of Anticancer Agents", Oncology Graduate School of Amsterdam, December, 1998.

Invited Speaker, British Cancer Research Meeting, Leeds, UK, June, 2001.

Invited Speaker, 7th International Symposium on Cancer Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan, December, 2002.

Invited Speaker, EORTC Pharmacology and Molecular Mechanisms Group Meeting, Copenhagen, Denmark, January, 2002.

Keynote Speaker, British Association for Cancer Research, Special Conference "Cancer Drug Discovery: the molecular target/chemistry interface", Oxford, UK, September 8-10, 2002.

Invited Speaker, 8th International Symposium on Cancer Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan, December, 2003.

Invited Speaker, Gordon Research Conference on Molecular Therapeutics of Cancer, Colby-Sawyer College, New London, NH, July, 2004.

Invited Speaker, symposium on the "Chemistry Biology Interface: Synergistic New Frontiers", New Delhi, INDIA, November 2004.

Invited speaker, EORTC Pharmacology and Molecular Mechanisms Group Meeting, Berlin, 2007.

ACADEMIC APPOINTMENTS:

Instructor of Anatomy (Histology), Uniformed Services University of the Health Sciences, School of Medicine, Bethesda, Maryland, October, 1976 - May, 1977.

Lecturer in Biology (Genetics), the University of Akron, Akron, Ohio, Fall, 1979.

Assistant Professor of Experimental Pathology, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, July, 1978-November, 1981.

AWARDS:

United States Public Health Service Traineeship, Academic Year 1974-1975, Grant Number 5 Tol Es0017-07.

Joint Service Commendation Medal for Service at the Armed Forces Institute of Pathology, awarded June 30, 1977.

National Institutes of Health Merit Award, shared with Dr. Michael Currens, "For design, implementation, and management of novel drug screens for AIDS and opportunistic infection-related targets", 2001.

PROFESSIONAL CERTIFICATION:

Board Certified, American Board of Medical Genetics, Medical Geneticist Specialty, 1982.

EDITORIAL BOARD MEMBERSHIP:

Journal of the National Cancer Institute, 1992-present

Journal of Molecular Medicine, September 2004-present

Cancer Science (formerly Japanese Journal of Cancer Research – Gann), 2004 – present

Journal of Experimental Therapeutics and Oncology, 1995- present

Oncology Reports, 1994-1997

Stem Cells (formerly International Journal of Cell Cloning), 1986-1993

Invasion and Metastasis, 1990-1995

PROFESSIONAL AFFILIATIONS:

American Association for Cancer Research

MILITARY STATUS:

Lt. Colonel, Medical Service Corps, U.S. Army Reserve (Retired).

Principal or Co-Principal Investigator for Government Collaborative Research and Development Agreements (CRADAs):

Phytobiotech, Inc., Laval, Canada: Identification of Novel Antitumor and Antimicrobial Agents Through Screening of Naturally-Derived Phytochemical Libraries

University of Pennsylvania (Robert Ricciardi, Ph.D.), MTA-CRADA: Targeted-Screening for Inhibitors of Human Herpesvirus 8 DNA Polymerase

Principal or Co-Principal Investigator for Government Collaborative Research and Development Agreements (CRADAs):

ChemBridge Corporation, San Diego, California, MTA-CRADA: Supply of Chemical Libraries for Use in Targeted-Screening for Inhibitors of Human Hepesvirus 8 DNA Polymerase

Albany Molecular Research, Inc., Albany, NY: Utilization of BIOACTIV™ for the development of Compound Derivatives

Novuspharma, Milan, Italy: Development of inhibitors of the Hypoxia Inducible Factor (HIF-1) Transcriptional Activation Pathway

TopoTarget, Copenhagen, Denmark: Clinical Evaluation of PDX-101, a Novel HDAC Inhibitor and Development of Second Generation HDAC Inhibitors

Merlion Pharmaceuticals, Singapore: Screening of MerLion's Natural Products for Novel Small Molecule Inhibitors of the Hypoxic Signaling Pathway (CRADA # 02069)

Sigma Tau Industrie Farmaceutische Riunite S.p.A., Milan, Italy: Evaluation of Topoisomerase I Inhibitors as Antitumor Inhibitors of Hypoxia Inducible Factor 1 (M-CRADA # 01893)

PATENTS:

Pommier Yves; Shoemaker, Robert H.; Scudiero, Domonic; Currens, Michael; Cardellina, John; Jobson, Andrew. Use of Chk2 kinase inhibitors for cancer treatment. PCT Int. Appl. (2007) WO 2007016338

Sei, Shizuko; Marquez; Victor; Shoemaker, Robert H.

North-2'-deoxy-methanocarbothymidines as antiviral agents for the treatment of Kaposi's sarcoma-associated herpes virus and for the treatment of Kaposi's sarcoma. PCT Int. Appl. (2006), WO 2006113204

Shoemaker, Robert H.; Currens, Michael; Rein, Alan; Feng; Ya-Xiong; Fisher, Robert; Stephen, Andrew; Worthy, Karen; Sei, Shizuko; Crise, Bruce; Henderson, Louis E.

Stibonic acid compounds and diphenyl compounds for inhibiting viral replication. PCT Int. Appl. (2004) WO 2004032869

Boyd, Michael R.; Gustafson, Kirk R.; Shoemaker, Robert H.; McMahon, James B.;

Isolation, cloning and sequence of antiviral cyanovirin-N proteins and peptides from Nostoc elliposporum. U.S. (1998) Cont.-in-part of U.S. Ser. No. 429, 965 US 5821081

Boyd, Michael R.; Gustafson, Kirk R.; Shoemaker, Robert H.; McMahon, James B.

Antiviral cyanovirin proteins, synthetic DNA coding sequences for its recombinant production and activity against HIV-1 virus. PCT Int. Appl. (1996) WO 9634107

BIBLIOGRAPHY

1. Fisher, E.R., Gregorio, R., Shoemaker, R.H., Horvat, B., and Hubay, C. The Derivation of So-Called "Giant-Cell" and "Spindle-Cell" Undifferentiated Thyroidal Neoplasms. *American Journal of Clinical Pathology* 61: 680-689, 1974.
2. Fisher, E.R., Wholey, M., and Shoemaker, R.H. Cigarette Smoking and Cholesterol Atherosclerosis of Rabbits. *Archives of Pathology* 98: 418-421, 1974.
3. Fisher, E.R., Shoemaker, R.H., and Sabnis, A. Relationship of Hyperplasia to Cancer in MCA-Induced Mammary Tumorigenesis. *Laboratory Investigation* 33: 33-42, 1975.
4. Fisher, E.R., Shoemaker, R.H., and Palekar, A.S. Identification of Premalignant Hyperplasia in Methylcholanthrene Induced Mammary Tumorigenesis. *Laboratory Investigation* 33: 446-450, 1975.
5. Shoemaker, R.H. X Chromatin and Aging. *Acta Cytologica* 21: 127-131, 1977.
6. Fletcher, R.D., Shoemaker, R.H., and Albertson, J.N. Desmosomes Observed in a Gingival Cell Line. *Journal of Dental Research* 56: 1106, 1977.
7. Lake, R.S., Kropko, M.L., Pezzutti, M.R., Shoemaker, R.H., and Igel, H.J. Chemical Induction of Unscheduled DNA Synthesis in Human Skin Epithelial Cell Cultures. *Cancer Research* 38: 2091-2098, 1978.
8. Lake, R.S., Kropko, M.L., McLachlan, S., Pezzutti, M.R., Shoemaker, R.H., and Igel, H.J. Chemical Induction of DNA Repair Synthesis in Human Peripheral Blood Monocytes. *Mutation Research* 74: 357-377, 1980.
9. Shoemaker, R.H., Abbott, B.J., Macdonald, M.M., Mayo, J.G., Venditti, J.M., and Wolpert-DeFilippes, M.K. Use of the KB Cell Line for In Vitro Cytotoxicity Assays. *Cancer Treatment Reports* 67: 97, 1983.
10. Shoemaker, R.H., Wolpert-DeFilippes, M.K., and Venditti, J.M. Application of a Human Tumor Clonogenic Assay to Screening for New Antitumor Drugs. *Proceedings of the 13th International Congress of Chemotherapy*, 223/14-223/19, 1983.
11. Shoemaker, R.H., Curt, G.A., and Carney, D.N. Evidence for Multi-Drug Resistant Cells in Human Tumor Cell Populations. *Cancer Treatment Reports* 67: 883-888, 1983.
12. Shoemaker, R.H., Wolpert-DeFilippes, M.K., and Venditti, J.M. Potentials and Drawbacks of the Human Tumor Stem Cell Assay. *Behring Institute Mitteilungen* 74: 262-272, 1984.

13. Shoemaker, R.H., Wolpert-DeFilippes, M.K., Melnick, N.R., Venditti, J.M., Simon, R.M., Kern, D.H., Lieber, M.M., Miller, W.T., Salmon, S.E., and Von Hoff, D.D. Recent Results of New Drug Screening Trials with a Human Tumor Colony Forming Assay. In: Human Tumor Cloning, S. Salmon and J. Trent (Eds.), Grune & Stratton, Orlando, Florida, 1984, pp. 345-355.
14. Weisenthal, L.M., Shoemaker, R.H., Marsden, J.A., Dill, P.L., Baker, J.A., and Moran, E.M. In Vitro Chemosensitivity Assay Based on the Concept of Total Tumor Cell Kill. *Recent Results in Cancer Research* 94: 161-173, 1984.
15. Shoemaker, R.H., Wolpert-DeFilippes, M., Kern, D., Lieber, M., Makuch, R., Miller, W., Salmon, S., Venditti, J., and Von Hoff, D. Application of a Human Tumor Colony Forming Assay to New Drug Screening. *Cancer Research* 45: 2145-2153, 1985.
16. Marsh, J.M., Shoemaker, R.H., and Suffness, M. Stability of the In Vivo P388 Leukemia Model in Evaluation of Antitumor Activity of Natural Products. *Cancer Treatment Reports* 69: 683-685, 1985.
17. Shoemaker, R.H. New Approaches to Antitumor Drug Screening: The Human Tumor Colony Forming Assay. *Cancer Treatment Reports* 70: 9-12, 1986.
18. Appel, P.L., Alley, M.C., Lieber, M.M., Shoemaker, R.H., and Powis, G. Metabolic Stability of Experimental Chemotherapeutic Agents in Hepatocyte: Tumor Cell Co-Cultures. *Cancer Chemotherapy and Pharmacology* 17: 47-52, 1986.
19. Taetle, R., Honeysett, J. M., Rosen, F., Shoemaker, R. H. Use of Nude Mouse Xenografts as Preclinical Drug Screens: Further Studies on In Vitro Growth of Xenograft Tumor-Colony Forming Cells. *Cancer* 58: 1969-1978, 1986.
20. Shoemaker, R., Wolpert-DeFilippes, M., Plowman, J., Abbott, B., Venditti, J., Trader, M., Griswold, D., Gerlach, J., and Ling, V. Pleiotropic Resistance and Drug Development. *Progress in Clinical and Biological Research* 223: 143-149, 1986.
21. Scheithauer, W., Clark, G.M., Salmon, S.E., Dorda, E., Shoemaker, R.H., and Von Hoff, D.D. A Model for Estimation of Clinically Achievable Plasma Concentrations for Investigational Anticancer Drugs in Man. *Cancer Treatment Reports* 70: 1379-1382, 1986.
22. McLemore, T.L., Blacker, P.C., Gregg, M., Jessee, S.E., Alley, M.C., Abbott, B.J., Shoemaker, R.H., Litterst, C.C., Hubbard, W.C., Brennan, R.H., Fine, D.L., Eggleston, J.C., Mayo, J.G., and Boyd, M.R. Intrabronchial Implantation: A Method for the Orthotopic Propagation of Human Lung Tumors in Athymic Nude Mice. *Chest* 91(Supplement): 55-85, 1987.

23. Gazdar, A., Shoemaker, R., Mayo, J., Donovan, P., and Fine, D. Human Lung Cancer Xenografts and Metastases in Athymic (Nude) Mice. In: Immune-Deficient Animals in Biomedical Research, Rygaard, Brunner, Graem, Spang-Thomsen (Eds.) Karger, Basel, 1987, pp. 277-280.
24. McLemore, T.L., Blacker, P.C., Gregg, M., Alley, M.C., Abbott, B.J., Shoemaker, R.H., Liu, M.C., Litterst, C.C., Hubbard, W.C., Brennan, R.H., Fine, D.L., Bohlman, M.E., Eggleston, J.C., Mayo, J.G., and Boyd, M.R. A Novel Intrapulmonary Model for the Orthotopic Propagation of Human Lung Cancers in Athymic Nude Mice. *Cancer Research* 47: 5132-5140, 1987.
25. Fine, D., Shoemaker, R., Gazdar, A., Mayo, J., Fodstad, O., Boyd, M., Abbott, B., and Donovan, P. Metastatic Models of Human Tumors in Athymic Mice: Useful Models for Drug Development. *Cancer Detection and Prevention* 1(Suppl): 291-299, 1987.
26. Gorelik, E., Ovejera, A., Shoemaker, R., Jarvis A., Alley, M., Duff, R., Mayo, J.G., Herberman, R.B., and Boyd, M.R. Microencapsulated Tumor Assay: New Short-Term Assay for In Vivo Evaluation of the Effects of Anticancer Drugs on Human Tumor Cell Lines. *Cancer Research* 47: 5739-5747, 1987.
27. Marsh, J.C., Shoemaker, R.H., Salmon, S.E., Kern, D.H., and Venditti, J.M. Relationship Between In Vitro Tumor Stem Cell Assay and In Vivo Antitumor Activity Using the P388 Leukemia. *International Journal of Cell Cloning* 6: 60-68, 1988.
28. Boyd, M.R., Shoemaker, R.H., Cragg, G.M. and Suffness, M. New Avenues of Investigation of Marine Biologicals in the Anticancer Drug Discovery Program of the National Cancer Institute. In: Pharmaceuticals and the Sea. Jefford, C.W., Rinehart, K.L., and Shield, L.S. (Eds.) Technomic Publishing Co. Inc., Lancaster, PA, 1988, pp. 27-44.
29. Shoemaker, R.H., McLemore, T.L., Abbott, B.J., Fine, D.L., Gorelik, E., Mayo, J.G., Fodstad, O., and Boyd, M.R. Human Tumor Xenograft Models for Use With an In Vitro Based, Disease-Oriented Antitumor Drug Screening Program. In: Human Tumor Xenografts in Anticancer Drug Development. Winograd, B., Peckham, M.G., and Pinedo H.M. (Eds.), European School of Oncology Monograph, Springer-Verlag, Berlin, 1988, pp. 115-120.
30. Alley, M.C., Scudiero, D.A., Monks, A., Hursey, M.L., Czerwinski, M.J., Fine, D.L., Abbott, B.J., Mayo, J.G., Shoemaker, R.H., and Boyd, M.R. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. *Cancer Research* 48:589-601, 1988.
31. Shoemaker, R., Alley, M., Scudiero, D., Monks, A., Fine, D., McLemore, T., Abbott, B., Mayo, J., and Boyd, M. Development of Human Tumor Cell Lines for Use in Disease-Oriented Drug Screening. In: Progress in Chemotherapy. B. Berkarda and H.P. Kuemmerle (Eds), Ecomed, Landsberg/Lech, Federal Republic of Germany, 1988.

32. Scudiero, D., Shoemaker, R., Paull, K., Alley, M., Monks, A., Tierney, S., Nofzinger, T., Currens, M., Burkew, D., and Boyd, M. Evaluation of a Soluble Tetrazolium/Formazan Assay for Growth and Drug Sensitivity in Culture. *Cancer Research* 48: 4827-4833, 1988.
33. Kern, D.H., Driscoll, J.D., Hildebrand-Zanki, S.U., and Shoemaker, R.H. Structure-Activity Studies of Catechol Analogs with Selective Cytotoxicity for Malignant Melanoma. In: Progress in Chemotherapy. B. Berkarda and H.P. Kuemmerle (Eds), Ecomed, Landsberg/Lech, Federal Republic of Germany, 1988, pp. 585-587.
34. McLemore, T.L., Eggleston, J.C., Shoemaker, R.H., Abbott, B.J., Bohlman, M.E., Liu, M.C., Fine, D.L., Mayo, J.G. and Boyd, M.R. Comparison of Intrapulmonary Percutaneous Intrathoracic, and Subcutaneous Models for the Propagation of Human Pulmonary and Non-Pulmonary Cancer Cell Lines in Nude Mice. *Cancer Research* 48:2880-2886, 1988.
35. Paull, K.D., Shoemaker, R.H., Boyd, M.R., Parsons, J.L., Risbood, P.A., Barbera, W.A., Sharma, M.N., Baker, D., Hand, E., Scudiero, D., Monks, A., Alley, M., and Grote, M. The Synthesis of XTT: A New Tetrazolium Reagent Bio reducible to a Water Soluble Formazan. *Journal of Heterocyclic Chemistry* 25: 911-914, 1988.
36. Kern, D.H., Shoemaker, R.H., Hildebrand-Zanki, S.U., and Driscoll, J.S. Catechol Analogs with Selective Cytotoxicity for Human Malignant Melanoma: Structure Activity Relationships. *Cancer Research* 48: 5178-5182, 1988.
37. Vickers, P.J., Dickson, R.B., Shoemaker, R.H, and Cowan, K.H. A Multidrug-Resistant MCF- 7 Human Breast Cancer Cell Line Which Exhibits Cross-Resistance to Antiestrogens and Hormone-Independent Tumor Growth In Vivo. *Molecular Endocrinology* 2(10): 886-892, 1988.
38. Shoemaker, R.H., Monks, A., Alley, M.C., Scudiero, D.A., Fine, D.L., McLemore, T.L., Abbott, B.J., Paull, K.D., Mayo, J.G., and Boyd, M.R. Development of Human Tumor Cell Line Panels for Use in Disease-Oriented Drug Screening. *Progress in Clinical and Biological Research* 276: 265-286, 1988.
39. Vince R., Hua, M., Brownell, J., Daluge, S., Lee, F., Shannon, W.M., Lavelle, G.C., Qualls, K.J., Weislow, O.S., Kiser, R., Cannonico, P.G., Schultz, R.J., Narayanan, V.L., Mayo, J.G., Shoemaker, R.H., and Boyd, M.R. Potent and Selective Activity of a New Carbocyclic Nucleoside (Carbovir: NSC 614846) Against Human Immunodeficiency Virus In Vitro. *Biochemical and Biophysical Research Communications* 156: 1046-1053, 1988.
40. Shoemaker, R.H. An In Vitro Approach to Disease-Oriented Antitumor Drug Screening: The Human Tumor Colony Forming Assay. In: Horizons on Antibiotic Research. Davis, B.D., Ichikawa, T., Maeda, K., and Mitscher, L.A. (Eds.) Japan Antibiotics Research Association, Tokyo, 1988, pp. 66-73.

41. Boyd, M.R., Shoemaker, R.H., McLemore, T.L., Johnston, M.R., Alley, M.C., Scudiero, D.A., Monks, A., Fine, D.L., Mayo, J.G., and Chabner, B.A. Drug Development. In: Thoracic Oncology. Roth, J.A., Ruckdeschel, J.C., and Weisenburger, T.H. (Eds.) W.B. Saunders Co. Philadelphia, PA, 1989, pp. 711-722.
42. Weislow, O.S., Kiser, R., Fine, D.L., Bader J., Shoemaker, R.H., and Boyd, M.R. New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity. *Journal of the National Cancer Institute* 81: 577-586, 1989.
43. Paull, K.D., Shoemaker, R.H., Hodes, L., Monks, A., Scudiero, D.A., Rubinstein, L., Plowman, J., and Boyd, M.R. Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. *Journal of the National Cancer Institute* 81: 1088-1092, 1989.
44. Lebsanft, J., McMahon, J.B., Steinmann, G.G., and Shoemaker, R.H. A Rapid In Vitro Method for the Evaluation of Potential Antitumor Drugs Requiring Metabolic Activation by Hepatic S9 Enzymes. *Biochemical Pharmacology* 38: 4477-4483, 1989.
45. McMahon, J., Schmidt, S., Weislow, O., Stinson, S., Camalier, R., Gulakowski, R., Shoemaker, R., Kiser, R., Dykes, D., Harrison, S., Mayo, J., and Boyd, M. Feasibility of Cellular Microencapsulation Technology for the Evaluation of Anti-HIV Drugs in Vivo. *Journal of the National Cancer Institute* 82: 1761-1765, 1990.
46. Rubinstein, L.V., Shoemaker, R.H., Paull, K.D., Simon, R.M., Tosini, S., Skehan, P., Scudiero, D.A., Monks, A., and Boyd, M.R. Correlation of In Vitro Anticancer Drug Screening Data Generated with a Tetrazolium Assay (MTT) Versus a Protein Assay (SRB) Against a Diverse Panel of Human Tumor Cell Lines. *Journal of the National Cancer Institute* 82: 1113-1118, 1990.
47. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a High-Flux Anticancer Drug Screen Utilizing a Diverse Panel of Cultured Human Tumor Cell Lines. *Journal of the National Cancer Institute* 83: 757-766, 1991.
48. Shoemaker, R.H., Dykes, D.J., Plowman, J., Harrison, S.D., Griswold, D.P., Abbott, B.J., Mayo, J.G., Fodstad, O., and Boyd, M.R. Practical Spontaneous Metastasis Model for In Vivo Therapeutic Studies Using a Human Melanoma. *Cancer Research* 51: 2837-2841, 1991.
49. Licht, T., Fiebig, H.H., Bross, K.J., Herrmann, F., Berger, D.P., Shoemaker, R.H., and Mertelsmann, R. Induction of Multiple-Drug Resistance During Anti-Neoplastic Chemotherapy In Vitro. *Int. J. Cancer* 49: 630-637, 1991.

50. Wu, L., Smythe, A.M., Stinson, S.F., Mullendore, L., Monks, A., Scudiero, D.A., Paull, K.D., Koutsoukos, A.D., Rubinstein, L.A., Boyd, M.R., and Shoemaker, R.H. Multidrug-Resistant Phenotype of Disease-Oriented Panels of Human Tumor Cell Lines Used for Anticancer Drug Screening. *Cancer Research* 52: 3029-3034, 1992.
51. Masters, J.R.W., Jenkins, W.E.A., and Shoemaker, R.H. Screening of New Anticancer Agents In Vitro Using Panels of Human Cell Lines Derived from Non-Seminomatous Germ Cell Tumours and Transitional Cell Carcinomas of the Bladder. *Eur. J. Cancer* 28A: 1617-1622, 1992.
52. Louie, K.G., Hamilton, T.C., Shoemaker, R.H., Young, R.C., and Ozols, R.F. Evaluation of In Vitro Drug Screening Leads Using Experimental Models of Human Ovarian Cancer. *Investigational New Drugs* 10:73-78, 1992.
53. Shoemaker, R.H., Smythe, A.M., Lin, W., Balaschak, M.S., and Boyd, M.R. Evaluation of Metastatic Human Tumor Burden and Response to Therapy in a Nude Mouse Xenograft Model Using a Molecular Probe for Repetitive Human DNA Sequences. *Cancer Research* 52:2791-2796, 1992.
54. Fisherman, J.S., Osborn, B.L., Chun, H.G., Plowman, J., Smith, A., Christian, M.C., Zaharko, D., and Shoemaker, R.H. Chloroquinoxaline Sulfonamide: A Sulfanilamide Antitumor Agent Entering Clinical Trials. *Investigational New Drugs* 11:1-9, 1993.
55. Beutler, J.A., Cardellina, J.H., Gray, G.N., Prather, T.R., Shoemaker, R.H., Boyd, M.R., Lin, C.M., Hammel, E., and Cragg, G.M. Two New Cytotoxic Chalcones from Calythropsis aurea. *Journal of Natural Products* 56:1718-1722, 1993.
56. Johnson, B.E., Parker, R., Tsai, C.M., Baltz, J., Miller, M.J., Shoemaker, R., Phelps, R., Bastian, A., Stocker, J., Phares, J., Mulshine, J.L., Gazdar, A.F., and Ihde, D.C. Phase I Trial of Dihydroleupenone in Lung Cancer Patients, A Novel Compound with In Vitro Activity Against Lung Cancer. *Investigational New Drugs* 11:29-37, 1993.
57. Beutler, J.A., Cardellina, J.H., Prather, T., Shoemaker, R.H., Boyd, M.R., and Snader, K.M. A Cytotoxic β -Carboline from the Bryozoan Catenicella cribraria. *Journal of Natural Products* 56:1825-1826, 1993.
58. Acton, E.M., Narayanan, V.L., Risbood, P., Shoemaker, R.H., Vistica, D.T., and Boyd, M.R. Anticancer Specificity of Some Ellipticinium Salts Against Human Brain Tumors In Vitro. *Journal of Medicinal Chemistry* 37:2185-2189, 1994.
59. Peters, A.C., Smythe, A.M., Wu, L., Monks, A., Boyd, M.R., and Shoemaker, R. H., Levels of mRNA Coding for DNA Topoisomerase II Isoforms Do Not Correlate With In Vitro Drug Sensitivity. *Oncology Reports* 1:907-911, 1994.

60. Fuller, R.W., Cardellina, J.H., Jurek, J., Scheuer, P.J., Alvarado-Lindner, B., McGuire, M., Gray, G.N., Steiner, J.R., Clardy, J., Menez, E., Shoemaker, R.H., Newman, D.J., Snader, K.M., and Boyd, M.R. Isolation and novel structure/activity features of halomon-related antitumor compounds from the red alga Portieria hornemannii. *Journal of Medicinal Chemistry* 37:4407-4411, 1994.
61. Beutler, J.A., Cardellina, J.H., McMahon, J.B., Shoemaker, R.H., and Boyd, M.R. Antiviral and antitumor plant metabolites. In: Arnason J.T. et al. (eds.), Phytochemistry of Medicinal Plants. Plenum Press, New York (1995), pp. 47-64.
62. Shoemaker, R.H., Balaschak, M.S., Alexander, M.R., and Boyd, M.R. Therapeutic activity of 9-chloro-2-methylellipticinium acetate in an orthotopic model of human brain cancer. *Oncology Reports* 2:663-667, 1995.
63. Hallock, Y.F., Cardellina, J.H., Balaschak, M.S., Alexander, M.R., Prather, T.R., Shoemaker, R.H., and Boyd, M.R. Antitumor activity and stereochemistry of acetylenic alcohols from the sponge Cribrochalina vasculum. *J. Natural Products* 58:1801-1807, 1995
64. Izquierdo, M.A., Shoemaker, R.H., Flens, M.J., Scheffer, G.L., Wu, L., Prather, T.R., and Scheper, R.J. Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. *International Journal of Cancer* 65: 230-237, 1996.
65. McMahon, J.B., Buckheit, R.W., Gulakowski, R.J., Currens, M.J., Vistica, D.T., Shoemaker, R.H., Stinson, S.F., Russel, J.D., Bader, J.P., Narayanan, V.L., Schultz, R.J., Brouwer, W.G., Felauer, E.E., and Boyd, M.R. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. *Journal of Pharmacology and Experimental Therapeutics* 276:298-305, 1996.
66. Stein, U., Shoemaker, R.H., and Schlag, P.M. MDR-1 gene expression: Evaluation of a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. *European Journal of Cancer* 32A:86-92, 1996.
67. Jensen, P.B. and Shoemaker, R.H. Preclinical Drug Development, In: Hirsch, F.R. (Ed), Lung Cancer: Prevention, Diagnosis, and Treatment, Bristol-Meyers Squibb, Copenhagen, Denmark, 1996, pp. 121-142.
68. Shoemaker, R.H., Lewensohn, R., Kristjansen, P., and Jensen, P.B. Current Status and Future Perspectives in Preclinical Testing in Lung Cancer, In: Hirsch, F.R. (Ed), Lung Cancer: Prevention, Diagnosis, and Treatment, Bristol-Meyers Squibb, Copenhagen, Denmark, 1996, pp. 143-146.

69. Stein, U., Walther, W., and Shoemaker, R.H. Vincristine induction of mutant and wildtype human multidrug-resistance promoters is cell-type specific and dose-dependent. *Journal of Cancer Research and Clinical Oncology* 122:275-282, 1996.
70. Arguello, F., Sterry, J.A., Zhao, Y.Z., Alexander, M.R.A., Shoemaker, R.H., and Cohen, H.J. Two serologic markers to monitor the engraftment, growth and treatment response of human leukemias in SCID mice. *Blood* 87:4325-4332, 1996.
71. Bernart, M.W., Cardellina, J.H., Balaschak, M.S., Alexander, M., Shoemaker, R.H., and Boyd, M.R. Cytotoxic falcarinol oxylipins from Denropanax arboreus. *Journal of Natural Products* 59:748-753, 1996.
72. Stein, U., Walther, W., and Shoemaker, R.H. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. *Journal of the National Cancer Institute* 88:1383-1392, 1996.
73. Scheper, R.J., Scheffer, G.L., Flens, M.J., Van der Valk, P., Meijer, C.J.L.M., Pinedo, H.M., Clevers, H.C., Slovak, M.L., Rome, L.H., Shoemaker, R.H., and Izquierdo, M.A. Role of LRP/Major vault protein in multidrug resistance. In: Multidrug Resistance in Cancer Cells: Cellular, Biochemical, Molecular, and Biological Aspects, Gupta, S. and Tsuruo, T. (Eds.), John Wiley & Sons, New York, pp. 109-118, 1996.
74. Stein, U., Walther, W., and Shoemaker, R.H. Modulation of MDR-1 expression by cytokines in human colon carcinoma cells: An approach for reversal of multidrug resistance. *British Journal of Cancer* 74:1384-1391, 1996.
75. Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Shoemaker, R.H., Rome, L.H., and Scheper, R.J. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. *Cytotechnology* 19:191-197, 1996.
76. Fodstad, O.F., Breistol, K., Pettit, G.R., Shoemaker, R.H., and Boyd, M.R. Comparative antitumor activity of halichondrins and vinblastine against human tumor xenografts. *Journal of Experimental Therapeutics and Oncology* 1:119-125, 1996.
77. Stein, U.S., Walther, W., Laurencot, C.M., Scheffer, G.L., Scheper, R.J., and Shoemaker, R.H. Tumor Necrosis Factor-Alpha and Expression of the Multidrug Resistance-Associated Genes LRP and MRP. *Journal of the National Cancer Institute* 89:807-813, 1997.

78. Boyd, M.R., Gustafson, K.R., McMahon, J.B., Shoemaker, R.H., O'Keefe, B.R., Mori, T., Gulakowski, R.J., Wu, L., Rivera, M.I., Laurencot, C.M., Buckheit, R.W., Nara, P.L., Cardellina, J.H., Pannell, L.K., Sowder, R.C., Henderson, L.E. Discovery of Cyanovirin-N, a Novel HIV (Human Immunodeficiency Virus)-Inactivating Protein that Binds Viral Surface Envelope Glycoprotein gp120; Potential Applications to Microbicide Development. *Antimicrobial Agents and Chemotherapy* 41:1521-1530, 1997.
79. Stein, U., Walther, W., and Shoemaker, R.H. Modulation of MDR-1 expression by cytokines in human colon cancer cells: An approach for reversal of multidrug resistance. (extended abstract of British J Cancer 74:1384, 1996 paper solicited for publication in a special volume focusing on new biological approaches to cancer treatment). *Biotherapy in Cancer* 1:53, 1997.
80. Mori, T., Shoemaker, R.H., Gulakowski, R.J., McMahon, J.B., and Boyd, M.R. Analysis of sequences required for bioactivity of cyanovirin-N, a potent anti-HIV protein isolated from a cultured cyanobacterium. *Biochemical and Biophysical Research Communications* 238:218-222, 1997.
81. Laurencot, C.M., Scheffer, G.L., Scheper, R.J., and Shoemaker, R.H. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cells. *International Journal of Cancer* 72:1021-1026, 1997.
82. Beutler, J.A., Kashman, Y., Pannell, L.K., Cardellina, J.H., Alexander, M.A., Balaschak, M., Prather, T., Shoemaker, R.H., and Boyd, M.R. Isolation and characterization of novel cytotoxic saponins from Archidendron ellipticum. *Bioorganic and Medicinal Chemistry* 5:1509-1517, 1997.
83. Mori, T., Shoemaker, R.H., McMahon, L.B., Gulakowski, R.J., Gustafson, K.R., and Boyd, M.R. Construction and enhanced cytotoxicity of a cyanovirin-N-pseudomonas exotoxin conjugate against human immunodeficiency virus-infected cells. *Biochemical and Biophysical Research Communications* 239:884-888, 1997.
84. O'Keefe, B.R., Beutler, J.A., Cardellina, J.H., Prather, T., Shoemaker, R.H., Sowder, R.C., Henderson, L.E., Pannell, L.K., and Boyd, M.R. Isolation of a novel Kunitz family protease inhibitor in association with tethya hemolysin from the sponge Tethya ingalli. *Journal of Natural Products* 60:1094-1099, 1997.
85. Mori, T., Gustafson, K.R., Pannell, L.K., Shoemaker, R.H., Wu, L., McMahon, J.B., and Boyd, M.R. Recombinant production of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein derived from a cultured cyanobacterium. *Protein Expression and Purification* 12:151-158, 1998.
86. Beutler, J.A., Shoemaker, R.H., Prather, T., and Boyd, M.R. Cytotoxic geranyl stilbenes from *Macaranga schweinfurthii*. *Journal of Natural Products* 61:1509-1512, 1998.

87. Walther, W., Stein, U., Fichtner, I., Naundorf, H., Alexander, M., Shoemaker, R.H., and Schlag, P.M. In vivo evaluation of a drug-inducible vector system for the combined gene- and chemotherapy of cancer. *Adv Exp Med Biol* 451:139-144, 1998.
88. Stein, U., Walther, W., Shoemaker, R.H., and Schlag, P.M. IL-2 gene transfer for chemosensitization of multidrug-resistant human colon cancer cells. *Adv Exp Med Biol* 451:145-149, 1998.
89. Shoemaker, R.H. Genetic and Epigenetic Factors in Anticancer Drug Resistance. *Journal of the National Cancer Institute* 92:4-5, 2000.
90. Walther, W., Stein, U., Shoemaker, R.H., and Schlag, P.M. Chemotherapy-Inducible Vector for Gene Therapy of Cancer. In: Methods in Molecular Medicine, Vol. 35, Gene Therapy of Cancer: Methods and Protocols, Walther, W. and Stein, U. (Eds.), Humana Press, Totowa, NJ, pp. 371-392, 2000.
91. Beutler, J.A., McCall, K.L., Herbert, K., Herald, D.L., Pettit, G.R., Johnson, T., Shoemaker, R.H., and Boyd, M.R. Novel cytotoxic diterpenes from *Casearia arborea* (Flacourtiaceae). *Journal of Natural Products* 63:657-661, 2000.
92. Walther, W., Stein, U., Fichtner, I., Alexander, M., Shoemaker, R.H., and Schlag, P.M. MDR1 promoter-driven tumor necrosis factor- α expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors. *Cancer Gene Therapy* 7:893-900, 2000.
93. Keskin, O., Bahar, I., Jernigan, R.L., Beutler, J.A., Shoemaker, R.H., Sausville, E.A., and Covell, D.G. Characterization of anticancer agents by their growth-inhibitory activity and relationships to mechanism of action and structure. *Anticancer Drug Discovery* 15:79-98, 2000.
94. Beutler, J.A., McCall, K.L., Herbert, K., Herald, D.L., Pettit, G.R., Johnson, T., Shoemaker, R.H., and Boyd, M.R. Cytotoxic clerodane diterpene esters from *Laetia corymbulosa*. *Phytochemistry* 55:233-236, 2000.
95. Sausville, E.A. and Shoemaker, R.H. Role of the National Cancer Institute in AIDS-related Drug Discovery. *Journal of the National Cancer Institute Monograph* 28:55-57, 2000.
96. Mikovits, J., Ruscetti, F., Zhu, W., Bagni, R., Dorjsuren, D., and Shoemaker, R. Potential signatures of viral infections in human hematopoietic cells. *Disease Markers* 17:173-178, 2001.
97. Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. *Journal of Medicinal Chemistry* 45:818-40, 2002.

98. Shoemaker, R.H. and Sausville, E.A. Drug Development. In: Oxford Textbook of Oncology, Second Edition, Souhami RL, Tannock I, Hohenberger P, and Horiot JC (Eds.), Oxford University Press, Oxford, 2002, pp. 781-788.
99. George L. Scheffer, Marcel J. Flens, Sandra Hageman, Miguel A. Izquierdo, Robert H. Shoemaker and Rik J. Scheper. The vascular endothelial cell protein C receptor is frequently expressed in epithelial tumor cells. *European Journal of Cancer* 38:1535-42, 2002.
100. Robert H. Shoemaker, Dominic A. Scudiero, Giovanni Melillo, Michael J. Currens, Anne P. Monks, Alfred A. Rabow, David G. Covell, and Edward A. Sausville. Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery. *Current Topics in Medicinal Chemistry* 2:229-246, 2002.
101. Anders Wallqvist, Alfred A. Rabow, Robert H. Shoemaker, Edward A. Sausville, and David G. Covell. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. *Molecular Cancer Therapeutics* 1:311-320, 2002.
102. George L. Scheffer, Mariska C. de Jong, Marcel J. Flens, Miguel A. Izquierdo, Robert H. Shoemaker and Rik J. Scheper. Increased expression of beta 2-microglobulin in multidrug-resistant tumor cells. *British Journal of Cancer* 86:1943-1950, 2002.
103. Annamaria Rapisarda, Badarch Uranchimeg, Dominic A. Scudiero, Mike Selby, Edward A. Sausville, Robert H. Shoemaker, and Giovanni Melillo. Identification Of Small Molecule Inhibitors of HIF-1 Transcriptional Activation Pathway. *Cancer Research* 62:4316-4324, 2002.
104. Andrew G. Stephen, Karen M. Worthy, Eric Towler, Judy A. Mikovits, Shizuko Sei, Paula Roberts, Quan-en Yang, Rhone K. Akee, Paul Klausmeyer, Thomas G. McCloud, Robert Gorelick, Lou Henderson, Alan Rein, David G. Covell, Michael Currens, Robert H. Shoemaker and Robert J. Fisher. Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. *Biochemical and Biophysical Research Communications* 296:1228-1237, 2002.
105. Dorjsuren, D., Badralmaa, Y., Mikovits, J., Li, A., Fisher, R., Ricciardi, R., Shoemaker, R., and Sei, S. Expression and purification of recombinant Kaposi's sarcoma-associated herpesvirus DNA polymerase using a baculovirus vector system. *Protein Expression and Purification* 29:42-50, 2003.
106. Wallqvist A, Monks A, Rabow AA, Thanki N, Shoemaker RH, Covell DG. Mining the NCI screening database: explorations of agents involved in cell cycle regulation. *Prog Cell Cycle Res.* 5:173-9, 2003.
107. Stephen, A.G., Rein, A., Fisher, R.J., and Shoemaker, R.H. The Nucleocapsid Protein as a Target for Novel Anti-HIV Drugs. *Current Drug Discovery*, August, 2003, pp. 33-36.

143. Joell J. Gills, Jaclyn LoPiccolo, Junji Tsurutani, Robert H. Shoemaker, Carolyn J. M. Best, Mones S. Abu-Asab, Jennifer Borojerdi, Noel A. Warfel, Erin R. Gardner, Matthew Danish, M. Christine Hollander, Shigeru Kawabata, Maria Tsokos, William D. Figg, Patricia S. Steeg and Phillip A. Dennis. Nelfinavir, a lead HIV protease inhibitor, is a broad spectrum, anti-cancer agent that induces ER stress, autophagy and apoptosis *in vitro* and *in vivo*. *Clinical Cancer Research* 13:5183-5194, 2007.
144. Maura Calvani, Daniela Trisciuglio, Cristina Bergamaschi, Robert Shoemaker, and Giovanni Melillo. Differential involvement of VEGF in the survival of hypoxic colon cancer cells. *Cancer Research* 68:285-291, 2008.
145. David T. Vistica, Paula M. Krosky, Susan Kenney, Robert H. Shoemaker. Immunohistochemical Discrimination Between the ASPL-TFE3 Fusion Proteins of Alveolar Soft Part Sarcoma. *Journal of Pediatric Hematology/Oncology* 30:46-52, 2008.
146. Aldo Andreani, Silvia Burnelli, Massimiliano Granaiola, Alberto Leoni, Alessandra Locatelli, Rita Morigi, Mirella Rambaldi, Lucilla Varoli, Natalia Calonghi, Concettina Cappadone, Giovanna Farruggia, Maddalena Zini, Claudio Stefanelli, Lanfranco Masotti, Norman S. Radin, and Robert H. Shoemaker. New Antitumor Imidazo[2,1-b]thiazole Guanyldrazones and Analogues. *Journal of Medicinal Chemistry* 51:809-816, 2008..
147. Paul Klausmeyer, Thomas G. McCloud, Badarch Uranchimeg, Giovanni Melillo, Dominic A. Scudiero, John H. Cardellina, and Robert H. Shoemaker. Separation and SAR Study of HIF-1 α Inhibitory Tubulosines from *Alangium cf. longiflorum*. *Planta Medica* DOI 10.1055/s-2008-1034315, published online 2008.

Tam Luong Nguyen, Michael J. Currens, Dominic A. Scudiero, Jeffrey A. Smith, Deborah A. Lannigan, Robert H. Shoemaker, Dan W. Zaharevitz, and Rick Gussio. Inactivation of ribosomal s6 kinase 2 (RSK2) by a chemically diverse set of established serine/threonine kinase inhibitors: mapping the binding interactions in the ATP pocket using molecular modeling. (In Preparation)

Tamara L. Meragelman, Dominic A. Scudiero, Louis Staudt, Eric Davis, Thomas G. McCloud, John H. Cardellina II, Robert H. Shoemaker. Inhibitors of NF-KB Activation Pathway from *Cryptocarya rugulosa*. (In Preparation)

Vikas Rishi, Sarah L. Heyerdahl, Won-Jun Oh, Dominic Scudiero, Robert H. Shoemaker, and Charles Vinson. Inhibition of DNA binding *in vitro* and *in vivo* of five B-ZIP dimers by 15 antimony-containing small-molecules. (In Preparation)

Luke H. Stockwin, David T. Vistica, Susan Kenney, David S. Schrump, Donna O. Butcher, Mark Raffeld, and Robert H. Shoemaker. Microarray Analysis of Alveolar Soft-Part Sarcoma (ASPS) Identifies Transcripts Involved in Angiogenesis, Metastasis and Myogenic Differentiation. (In Preparation)

Shizuko Sei, Jodie K. Mussio, Quan-en Yang, Kunio Nagashima, Ralph E. Parchment, Matthew C. Coffey, Robert H. Shoemaker, and Joseph E. Tomaszewski. Potentiation of Reoviral Oncolysis by Chemotherapeutic Agents in Non-Small Cell Lung Cancer Cells. (In Preparation)

Anne Monks, Curtis Hose, Patrick Pezzoli, Gordon Vansant, Maxwell Sehested Joseph Monforte, and Robert Shoemaker. Defining a set of genes dysregulated in response to the HDAC inhibitor PXD101 (belinostat). (In Preparation)

Ruud Oerlemans, Celia R Berkers, Yehuda G. Assaraf, George L. Scheffer, Huib Ovaa, Rob. H. Melen, Robert H. Shoemaker, Ben A.C. Dijkmans, Rik J. Scheper and Gerrit Jansen. Specific targeting of the chymotrypsin-like 26S proteasome activity with the novel cytotoxic peptide 4A6. (In Preparation).

Exhibit B

NIAID-100

Weight Change in SCID-hu Thy/Liv Mice Treated with
NSC 13778 by Twice-Daily Subcutaneous Injection





Exhibit B (figure 1)

Declaration Under 37 CFR 1.132 by Dr. Robert Shoemaker

NIAID-100

Implant p24, Viral RNA, and MHC-I Expression in
HIV-1-infected SCID-hu Thy/Liv Mice Treated with
NSC 13778 by Twice-Daily Subcutaneous Injection



* $P \leq 0.050$ compared to untreated infected mice by Mann-Whitney U test.

Exhibit B (figure 2)

Declaration Under 37 CFR 1.132 by Dr. Robert Shoemaker